Sequence-specific RNA-guided CRISPR-Cas nucleases have revolutionized biological research due to their ease of programmability. The widely used Cas9 from Streptococcus pyogenes (SpCas9) can be targeted to specific DNA sequences by an associated complementary guide RNA (gRNA), provided that a protospacer adjacent motif (PAM) of the form NGG is also present. Catalytically inactive SpCas9 ("dead" SpCas9 or dSpCas9) have been fused to transcriptional activation or repression domains to alter the expression of individual genes 1, 2 or to perform genome-wide library screens [3] [4] [5] in mammalian cells. Both small molecule-and light-inducible dSpCas9-based fusions have been developed [6] [7] [8] [9] [10] , enabling the ability to regulate the activity of this platform. Recently described CRISPR-Cpf1 nucleases offer additional capabilities beyond those of SpCas9 including shorter length CRISPR RNAs (crRNAs) for guiding Cpf1 to targets, the ability to target T-rich PAMs [11] [12] [13] , and RNase processing of multiple crRNAs from a single transcript by sequence-specific ribonuclease activity resident within Cpf1 itself 14, 15 . However, to our knowledge, "dead" Cpf1-based gene regulators have thus far only been shown to repress gene expression in bacteria 16, 17 and plant (Arabidopsis) 18 and have not been shown to function in mammalian cells either as activators or repressors. Here we describe both constitutively active and chemically inducible Cpf1-based transcriptional activator platforms for upregulating human gene promoters. We also demonstrate that facile expression of multiple crRNAs in a single transcript can be leveraged to achieve synergistic or combinatorial activation of endogenous genes in human cells.
We first tested whether we could upregulate endogenous human gene promoters with direct fusions of catalytically inactive Cpf1 nuclease to the strong synthetic VPR activator, which consists of four copies of the Herpes Simplex Virus-derived VP16 activator, the human NF-KB p65 activation domain, and the Epstein-Barr Virus-derived R transactivator (Rta) 19 ( Fig. 1a) .
Initial GFP reporter-based assay experiments showed that a "dead" Cpf1 from Lachnospiraceae bacterium ND2006 (dLbCpf1)-VPR fusion induced higher levels of gene activation than a "dead" Cpf1 from Acidaminococcus sp. BV3L6 (dAsCpf1)-VPR fusion (Supplementary Fig. 1 ).
This difference is consistent with previous reports from our group and others showing that LbCpf1 generally exhibits higher genome-editing activities than AsCpf1 in human cells 20, 21 .
Therefore, for all subsequent experiments described herein, we used the dLbCpf1 protein.
We next targeted the promoters of three different endogenous genes that are expressed at low levels in human HEK293 cells (HBB, AR and NPY1R) by designing three crRNAs for each promoter, located at various distances upstream of the transcription start point (Fig. 1a) .
Testing each of these crRNAs with the dLbCpf1-VPR fusion demonstrated robust transcriptional activation with at least one crRNA for each of the three target genes as assayed by measurement of transcription by real-time RT-PCR (Fig. 1b) . Testing of these same crRNAs with direct fusions of dLbCpf1 to the NF-KB p65 activation domain alone resulted in either little or no transcriptional activation of the target gene promoter (Fig. 1b) . Thus, as has been previously observed with dSpCas9-based activators, upregulation of gene expression by direct dLbCpf1 fusions is more efficient when multiple strong activation domains are recruited to a target promoter 3, 5, 19, 22 .
To extend the utility of dLbCpf1-based activators, we sought to construct drug-regulated versions of these effectors. To do this, we used the well-characterized DmrA and DmrC domains (fragments of the FK506-binding protein (FKBP) and FKBP-rapamycin-binding protein (FRB), respectively) that interact only in the presence of a rapamycin analog known as the A/C heterodimerizer 6, 23, 24 . We envisioned creating split dLbCpf1 activators consisting of two fusions: dLbCpf1 fused to a DmrA domain and a DmrC domain fused to VPR (Fig. 1c) . In this configuration, a reconstituted activator should assemble only in the presence of the A/C drug.
Testing of these bipartite fusions in the presence of the A/C heterodimerizer with single crRNAs (shown above to work efficiently with the direct dLbCpf1 activator fusions) failed to reveal activation of the HBB, AR or NPY1R genes (Fig. 1d) . We reasoned that increasing the number of DmrA domains linked to dLbCpf1 (and therefore the number of VPR domains recruited to the promoter) might increase the efficiency of gene activation. Testing of dLbCpf1 fusions harboring two, three or four tandem copies of the DmrA domain in the presence of DmrC-VPR revealed activation at two of the three endogenous gene promoters we tested (HBB and NPY1R; Fig.   1d ). Activation levels observed correlated with the number of DmrA domains, with maximum levels reaching approximately half of that observed with direct dLbCpf1-VPR fusions. As expected, activation was contingent on the presence of the A/C heterodimerizer drug (Fig. 1d) , demonstrating drug-dependency of this system. Surprisingly, we found that using DmrC-p65 fusions with dLbCpf1-DmrA fusions led to drug-dependent transcriptional upregulation from all three target gene promoters (Fig. 1d) , an unexpected result given the lack of activation observed with direct dLbCpf1-p65 fusions and these same crRNAs (Fig. 1b) . For HBB and NPY1R, the maximal levels of activation observed with DmrC-p65 were somewhat less (~50% and ~30%, respectively) than those obtained with DmrC-VPR but still robust in absolute terms (~20-fold and ~10-fold activation). For AR, DmrCp65 activated transcription by ~25-fold, showing superior activity relative to the lack of an effect by DmrC-VPR using the same crRNA.
One major advantage of Cpf1 compared to Cas9 is the ability to express multiple crRNAs within a single transcript that is subsequently processed into individual crRNAs by the RNase processing activity of Cpf1 (Fig. 2a) , thereby better enabling multiplex applications 14, 15, 17 . Expressing multiple gRNAs for SpCas9 from separate promoters can be challenging due to substantial recombination that can occur between promoter sequences and the crRNA:tracrRNA constant regions 25, 26 or the need for additional accessory RNA sequences or trans-acting factors if multiple gRNAs are expressed from a single transcript [26] [27] [28] [29] [30] [31] [32] . With Cpf1, multiple crRNAs can be encoded in one transcript, a capability that has been used previously to achieve multiplex gene editing in human cells 15 .
To test whether multiplex single transcript (MST) crRNAs might be used with dLbCpf1-based activators, we used the same sets of crRNAs we designed above for the HBB, AR or NPY1R genes and encoded sets of three crRNAs directed against a single promoter in one transcript ( Fig. 2b) . We reasoned that if a set of MST crRNAs were active in the same cell, then we might observe synergistic increases in transcription from the target gene promoter (Fig. 2b) , with synergy defined as greater than additive effects induced by two or more activators acting on the same promoter 2 . With direct fusions of VPR to dLbCpf1, we observed synergistic activation for two of the three endogenous human gene promoters (HBB and AR; Fig. 2c ). For the third gene promoter (NPY1R), we did not observe synergistic activation (Fig. 2c) . We also failed to observe synergistic activation of any of the three genes with direct fusion of p65 to dLbCpf1, with either MST crRNAs or separate crRNAs (Fig. 2c) , but this was not unexpected since none of these crRNAs individually activate transcription with dLbCpf1-p65 (Fig. 1b) .
These latter crRNAs might not be optimal for Cpf1 activation and the characteristics that define a robust crRNA remain to be elucidated in future experiments.
We also observed drug-dependent synergy with dLbCpf1-DmrA(x4) and DmrC-VPR at the HBB and AR promoters with MST crRNAs. As with the direct activator fusions, synergistic activation was not observed at the NPY1R promoter with MST crRNAs even though it was seen with individually expressed crRNAs introduced together (Fig. 2d) . A similar pattern of results for these three gene promoters was observed with dLbCpf1-DmrA(x4) and DmrC-p65 (Fig. 2d) .
The synergistic activation levels observed with DmrC-p65 on the HBB and AR genes were higher than comparable experiments performed with DmrC-VPR (Fig. 2d) .
Having established that multiple active crRNAs can be expressed from a single transcript, we next sought to determine whether MST crRNAs might be used to simultaneously up-regulate different endogenous human gene promoters in the same cells. To test this, we encoded three crRNAs, each already shown to robustly activate a different gene promoter with dLbCpf1-activators on a single transcript (Fig. 2e) . We found that these MST crRNAs could be used together with (i) dLbCpf1-VPR direct fusions, (ii) dLbCpf1-DmrA(x4) and DmrC-VPR fusions, or (iii) dLbCpf1-DmrA(x4) and DmrC-p65 fusions to simultaneously mediate transcriptional activation of the endogenous HBB, AR, and NPY1R gene promoters in human HEK293 cells (Fig. 2f) . The magnitudes of activation observed with the MST crRNAs were somewhat lower (~18 to 55%) compared with the same crRNAs expressed from separate expression vectors, suggesting that further optimization might be achieved by varying MST crRNA transcript architecture and/or protein and RNA stoichiometries. Nonetheless, these results demonstrate that as many as three crRNAs encoded in a single transcript can be used to simultaneously up-regulate transcription of multiple gene promoters using dLbCpf1-based activators.
To our knowledge, the results described here provide the first demonstration that Cpf1-derived proteins can be used regulate endogenous gene expression in human cells. The orthogonal PAM recognition specificities of wild-type LbCpf1 (TTTV) and two engineered Cpf1 variants 13 (TYCV and TATV) will enable an increased range of targetable sequences relative to what can be achieved with SpCas9 (NGG), a capability that should be particularly useful for genome-wide screens with RNA-guided gene regulatory proteins. Our success in using dCpf1
proteins to target two different activation domains (VPR and p65) should also motivate the engineering of dCpf1-based fusions bearing other heterologous regulatory domains (e.g., p300, DNMT, TET1) as has been previously done with dSpCas9 33, 34 Given that the genome-wide specificities of LbCpf1 nuclease are reported to be at least comparable (if not actually superior)
to those of SpCas9 nuclease 20, 21 , it seems likely that dLbCpf1 activators will be as specific as dSpCas9 activators, which have been shown to generally have minimal or no off-target gene activation events 22, 33 ; however, additional future experiments will be needed to confirm this.
Our work defines generalizable strategies for regulating and tuning the activities of RNAguided gene activator proteins. The bipartite activators we engineered enabled a useful on-off capability that responds to the cell-permeable A/C dimerizer drug, similar to other systems that have been described 10, 35 . In addition, increasing the number of DmrA dimerizer domains fused to dLbCpf1 enabled tuning of activation levels, presumably by increasing the number of DmrCactivator domain fusions recruited. These strategies could be easily extended to other functional domains beyond p65 and VPR and to more RNA-guided proteins such as other Cpf1 and Cas9
orthologues. In this regard, we note that we have successfully used these same strategies to regulate and tune dSpCas9-based activators (Supplementary Fig. 2 ) as have others who published similar drug-regulated dSpCas9-based activators while this work was in progress 8 .
We have also demonstrated that a key advantage of the Cpf1 platform, the ability to more easily encode multiple crRNAs on a single transcript, can be leveraged to enable 
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Plasmids and oligonucleotides
Diagram of constructs and a list of plasmids and related sequences used in this study are found in Supplementary Note 1; LbCpf1 target sites and multiplex crRNA sequences, and SpCas9 target sites are found Supplementary Table 1 . Plasmids dLbCpf1-p65 (JG1202) and dLbCpf1-VPR (JG1211) were constructed by cloning p65 and VPR domains into dLbCpf1(D832A) (MMW1578) using BstZ17I and Not I sites through isothermal assembly. VPR was amplified from SP-dCas9-VPR which was a gift from George Church (Addgene plasmid # 63798) 19 . Plasmids encoding dLbCpf1-DmrA(x1), dLbCpf1-DmrA(x2), dLbCpf1-DmrA(x3), and dLbCpf1-DmrA(x4) (JG674, JG676, JG693, and YET1000, respectively) were generated by subcloning dLbCpf1(D83A) into AgeI and XhoI digested constructs that have different numbers of DmrA domains (BPK1019, BPK1033, BPK1140, BPK1179 for dSpCas9-DmrA(x1) to dSpCas9-DmrA(X4), respectively) using isothermal assembly. Plasmids encoding 
Quantitative reverse transcription PCR
Total RNA was extracted from the transfected cells 72 hours post-transfection using the NucleoSpin® RNA Plus (Clontech, cat# 740984.250), and 250 ng of purified RNA was used for cDNA synthesis using High-Capacity RNA-cDNA kit (ThermoFisher, cat# 4387406). cDNA was diluted 1:20 and 3 ul of cDNA was used for quantitative PCR (qPCR). qPCR reaction samples were prepared using cDNA, SYBR (ThermoFisher, cat# 4385612), and primers detecting each target transcript. Primer sequences are listed in Supplementary Table 2 . qPCR was performed using Roche LightCycler480 with the following cycling protocols (Supplementary Table 2 (c) Schematic illustrating drug-dependent bi-partite dLbCpf1-based activator fusion proteins.
dLbCpf1 is fused to one to four DmrA domains and VPR or p65 is fused to a DmrC domain.
Because DmrA and DmrC interact only in the presence of a A/C-heterodimerizer drug (red diamond), the bi-partite activator is only reconstituted in the presence of the drug. (b) Relative differences in gene activation between direct fusions to dCas9 compared to drugdependent recruitment using DmrA and DmrC fusions, using either one or three sgRNAs targeted upstream of the VEGFA transcription start site. Gene activation assessed by VEGFA ELISA; error bars represent s.e.m. for n = 2, otherwise n = 1.
(c) Differences in VEGFA production based on DmrA repeat variation on dCas9-DmrA or DmrAdCas9, from 1 to 4 copies, using three sgRNAs targeted upstream of the VEGFA transcription start site. Gene activation assessed by VEGFA ELISA; error bars represent s.e.m. for n = 3.
